osimertinib
astrazeneca
['sclc', 'osimertinib', 'nsclc']
from #asco23: patients with resected, egfr-mutated, stage ib to iiia nsclc were randomly assigned to receive adjuvant osimertinib or placebo for 3 years. the 5-year overall survival was 88% with osimertinib &amp; 78% with placebo. via 
Thoracic Surgeon; Patient Advocate; Surgical Researcher; @MacThoracics @McMasterSurgery; @STJOESHAMILTON No specific medical advice given. Tweets by staff/WCH